Atlas Trials

A Study of Orelabrutinib in CLL/SLL Patients Who Are Slowly Responding to Ibrutinib

Clinical trial NCT05491044 · UNKNOWN

Trial details

NCT number
NCT05491044
Sponsor
Peking University People's Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
CLL/SLL
Start date
2022-01-01
Primary completion
2024-08-28
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.